

Date: 20 June 2025

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Scrip Symbol: SAILIFE	To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 Scrip Code: 544306
---	---

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Dear Sir/ Madam,

In continuation to the disclosure made in the prospectus of the initial public offering (Pg. No. 198 – “Facilities and Approvals”) and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) this is to inform you that the Company has successfully commenced commercial operation of the second phase of the production block with ≈91 kL of capacity at its facility in Bidar, Karnataka, India (“Unit IV Bidar Facility”) on 19th June 2025.

This is the second and final phase of the overall capacity addition of ≈195 kL which was under construction at Unit IV Bidar Facility as disclosed in the prospectus. Accordingly, the combined capacity of Unit IV Bidar Facility will be ≈640 kL which will be equipped to supply Registered Starting Materials (“RSM”), intermediates, and Active Pharmaceutical Ingredients (“APIs”) for both clinical and commercial purposes.

We request you to take note of the above.

Thank you.

For **Sai Life Sciences Limited**

RUNA
KARAN

Digitally signed by
RUNA KARAN
Date: 2025.06.20
11:52:58 +05'30'

Runa Karan
Company Secretary & Compliance Officer
Membership No.: A13721

Sai Life Sciences Limited (CIN: U24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey
#133, Gachibowli Miyapur Road,
Gachibowli, Hyderabad – 500032,
Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally
(V), Shameerpet Mandal, Medchal-Malkajgiri
(Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com